
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is a biotechnology company that has a positive outlook due to their focus on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology, and their potential to generate significant revenue through their royalty-bearing assets, including Jemperli and Imsidolimab. Their partnership with GSK and Vanda provides a strong revenue stream, potentially leading to important profitability and strategies to deliver value back to shareholders. With upcoming projected approvals and a potential stock buyback, AnaptysBio has the potential for significant growth and value creation.
Bears say
AnaptysBio is a clinical-stage biotechnology company focused on developing antibody products for autoimmune and inflammatory diseases. However, the company faces multiple risks inherent in the biotech sector, including clinical, regulatory, and commercial risk, and may require significant amounts of capital to continue developing clinical programs. Additionally, ongoing litigation with GSK and uncertainty around the success of its drug pipeline could impede the stock from reaching its potential. Overall, although their CRC program shows promising data, there are significant risks and uncertainties that make AnaptysBio's stock a high-risk investment.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares